Welcome to our dedicated page for NKGen Biotech SEC filings (Ticker: NKGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NKGen Biotech filings document a clinical-stage biotechnology issuer with common stock and warrants quoted on the OTC Expert Market and a capital structure that includes warrant rights and secured debt arrangements. Recent Form 8-K reports focus on material definitive agreements, including secured promissory notes, amendments to loan documents, secured convertible loan agreements and forward purchase agreement amendments involving the company and NKGen Operating Biotech, Inc.
The filings also identify NKGen as an emerging growth company and record corporate history tied to its former name, Graf Acquisition Corp. IV. Its regulatory documents provide formal disclosure of financing terms, subsidiary obligations, warrant exercise economics, governance status and market-quotation information for NKGN securities.
NKGen Biotech, Inc. reported that on January 12, 2026, it and its subsidiary NKGen Operating Biotech, Inc. amended an existing secured promissory note with AlpineBrook Capital GP I Limited. The amendment provides an additional $295,000 in funding, called the Second Additional New Loan, increasing the total principal amount of the note to $26,135,106.
The amendment also specifies how interest accrues on the different portions of the debt. Interest on $25,840,106 of principal continues to accrue from January 5, 2026, the date of the original note, while interest on the new $295,000 portion begins accruing from January 12, 2026, the date the amendment was executed.
NKGen Biotech, Inc. entered into a new secured promissory note with AlpineBrook Capital GP I Limited on January 5, 2026. The note has an original principal amount of $25,840,106, bears interest at 12% per year, and initially matures two months after issuance, with any extension at the lender’s discretion. It formalizes earlier undocumented cash advances totaling $25,540,106 and adds a new $300,000 advance.
The note cannot be prepaid before maturity without lender consent and includes a “most favored nation” clause requiring NKGen to match more favorable terms granted in future debt or equity financings. A Change of Control triggers cash repayment of principal and interest plus a cash premium equal to 20% of outstanding principal, while events of default increase the interest rate to 24% per year. The lender receives security interests over substantially all U.S. personal property of the borrowers, certain U.S. real property, and Korean collateral related to NKGen Biotech Korea, alongside restrictive covenants limiting additional debt, liens, and equity issuances.